Nephro-Urology Monthly

Published by: Kowsar

Overactive Bladder Syndrome and the Potential Role of Prostaglandins and Phosphodiesterases: An Introduction

Mohammad Sajjad Rahnama'i 1 , * , Gommert A. Van Koeveringe 1 and Philip E. Van Kerrebroeck 1
Authors Information
1 Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands
Article information
  • Nephro-Urology Monthly: September 01, 2013, 5 (4); 934-945
  • Published Online: September 10, 2013
  • Article Type: Review Article
  • Received: August 7, 2013
  • Accepted: September 15, 2013
  • DOI: 10.5812/numonthly.14087

To Cite: Rahnama'i M S, Van Koeveringe G A, Van Kerrebroeck P E. Overactive Bladder Syndrome and the Potential Role of Prostaglandins and Phosphodiesterases: An Introduction, Nephro-Urol Mon. 2013 ; 5(4):934-945. doi: 10.5812/numonthly.14087.

Abstract
Copyright © 2013, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Overactive Bladder Syndrome
3. Current Therapies for OAB
4. Anatomy of the Lower Urinary Tract
5. Histology of the Bladder Wall
6. Urothelium
7. Suburothelium
8. Muscle Layer
9. Bladder Physiology
10. Central Nervous System Control
11. Peripheral Control
12. The Role of Prostaglandins in Bladder Physiology
13. Prostaglandins in the Treatment of OAB
14. The Role of NO-cGMP in Bladder Physiology
15. Phosphodiesterase Inhibitors in the Treatment of OAB
Acknowledgements
Footnotes
References
  • 1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61(1): 37-49[PubMed]
  • 2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29(1): 4-20[DOI][PubMed]
  • 3. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000; 6(11 Suppl)-90[PubMed]
  • 4. Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol. 2007; 17(4): 231-6[DOI][PubMed]
  • 5. Komaroff AL, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med. 1996; 101(3): 281-90[DOI][PubMed]
  • 6. Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001; 57(6): 1044-50[PubMed]
  • 7. Coyne KS, Sexton CC, Thompson CL, Clemens JQ, Chen CI, Bavendam T, et al. Impact of overactive bladder on work productivity. Urology. 2012; 80(1): 97-103[DOI][PubMed]
  • 8. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004; 350(8): 786-99[DOI][PubMed]
  • 9. Chiaffarino F, Parazzini F, Lavezzari M, Giambanco V. Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol. 2003; 43(5): 535-8[PubMed]
  • 10. Goepel M, Hoffmann JA, Piro M, Rubben H, Michel MC. Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur Urol. 2002; 41(3): 234-9[PubMed]
  • 11. Cardozo L. The overactive bladder syndrome: treating patients on an individual basis. BJU Int. 2007; 99 Suppl 3: 1-7[DOI][PubMed]
  • 12. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004; 63(3): 461-5[DOI][PubMed]
  • 13. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87(9): 760-6[PubMed]
  • 14. Coyne KS, Margolis MK, Kopp ZS, Kaplan SA. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology. 2012; 79(1): 95-101[DOI][PubMed]
  • 15. Van Kerrebroeck PE. A treatment algorithm for the overactive bladder. BJU Int. 1999; 83 Suppl 2: 29-30[PubMed]
  • 16. Klotz T, Bruggenjurgen B, Burkart M, Resch A. The economic costs of overactive bladder in Germany. Eur Urol. 2007; 51(6): 1654-62[DOI][PubMed]
  • 17. Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R, et al. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity. Urol Int. 2012; 89(1): 1-8[DOI][PubMed]
  • 18. Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010; 29(1): 213-40[DOI][PubMed]
  • 19. Cardozo LD, Stanton SL. Genuine stress incontinence and detrusor instability--a review of 200 patients. Br J Obstet Gynaecol. 1980; 87(3): 184-90[PubMed]
  • 20. Feneley RC, Shepherd AM, Powell PH, Blannin J. Urinary incontinence: prevalence and needs. Br J Urol. 1979; 51(6): 493-6[PubMed]
  • 21. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004; 84(3): 935-86[DOI][PubMed]
  • 22. Andersson KE. Drugs and future candidates. Can Urol Assoc J. 2011; 5(5 Suppl 2)-3[DOI][PubMed]
  • 23. Engles CD, Hauser PJ, Abdullah SN, Culkin DJ, Hurst RE. Intravesical chondroitin sulfate inhibits recruitment of inflammatory cells in an acute acid damage "leaky bladder" model of cystitis. Urology. 2012; 79(2): 483 e13-7[DOI][PubMed]
  • 24. Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol. 2000; 278(6)-74[PubMed]
  • 25. Apodaca G. The uroepithelium: not just a passive barrier. Traffic. 2004; 5(3): 117-28[DOI][PubMed]
  • 26. Hicks RM. The mammalian urinary bladder: an accommodating organ. Biol Rev Camb Philos Soc. 1975; 50(2): 215-46[PubMed]
  • 27. Sun TT. Altered phenotype of cultured urothelial and other stratified epithelial cells: implications for wound healing. Am J Physiol Renal Physiol. 2006; 291(1)-21[DOI][PubMed]
  • 28. Liang FX, Riedel I, Deng FM, Zhou G, Xu C, Wu XR, et al. Organization of uroplakin subunits: transmembrane topology, pair formation and plaque composition. Biochem J. 2001; 355: 13-8[PubMed]
  • 29. Birder LA, Ruan HZ, Chopra B, Xiang Z, Barrick S, Buffington CA, et al. Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis. Am J Physiol Renal Physiol. 2004; 287(5)-91[DOI][PubMed]
  • 30. Wiseman OJ, Brady CM, Hussain IF, Dasgupta P, Watt H, Fowler CJ, et al. The ultrastructure of bladder lamina propria nerves in healthy subjects and patients with detrusor hyperreflexia. J Urol. 2002; 168(5): 2040-5[DOI][PubMed]
  • 31. Gillespie JI, Markerink-van Ittersum M, de Vente J. Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res. 2005; 321(3): 341-51[DOI][PubMed]
  • 32. Chopra B, Barrick SR, Meyers S, Beckel JM, Zeidel ML, Ford AP, et al. Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol. 2005; 562: 859-71[DOI][PubMed]
  • 33. Birder LA, Nealen ML, Kiss S, de Groat WC, Caterina MJ, Wang E, et al. Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci. 2002; 22(18): 8063-70[PubMed]
  • 34. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol. 2004; 240: 31-304[DOI][PubMed]
  • 35. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol. 2002; 22(3): 133-45[PubMed]
  • 36. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol. 2004; 74(6): 363-96[DOI][PubMed]
  • 37. Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci. 2002; 5(9): 856-60[DOI][PubMed]
  • 38. Birder LA, Kanai AJ, de Groat WC, Kiss S, Nealen ML, Burke NE, et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci U S A. 2001; 98(23): 13396-401[DOI][PubMed]
  • 39. Birder LA, Apodaca G, De Groat WC, Kanai AJ. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol. 1998; 275(2 Pt 2)-9[PubMed]
  • 40. Burnstock G. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci. 2001; 22(4): 182-8[PubMed]
  • 41. Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes--a possible sensory mechanism? J Physiol. 1997; 505 ( Pt 2): 503-11[PubMed]
  • 42. Mikhailidis DP, Jeremy JY, Dandona P. Urinary bladder prostanoids--their synthesis, function and possible role in the pathogenesis and treatment of disease. J Urol. 1987; 137(3): 577-82[PubMed]
  • 43. Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, et al. Non-neuronal cholinergic system in human bladder urothelium. Urology. 2006; 67(2): 425-30[DOI][PubMed]
  • 44. Birder LA, Kanai AJ, Cruz F, Moore K, Fry CH. Is the urothelium intelligent? Neurourol Urodyn. 2010; 29(4): 598-602[DOI][PubMed]
  • 45. Drake MJ, Fry CH, Eyden B. Structural characterization of myofibroblasts in the bladder. BJU Int. 2006; 97(1): 29-32[DOI][PubMed]
  • 46. Smet PJ, Jonavicius J, Marshall VR, de Vente J. Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience. 1996; 71(2): 337-48[PubMed]
  • 47. Gillespie JI, Markerink-van Ittersum M, de Vente J. cGMP-generating cells in the bladder wall: identification of distinct networks of interstitial cells. BJU Int. 2004; 94(7): 1114-24[DOI][PubMed]
  • 48. McCloskey KD, Gurney AM. Kit positive cells in the guinea pig bladder. J Urol. 2002; 168(2): 832-6[PubMed]
  • 49. Davidson RA, McCloskey KD. Morphology and localization of interstitial cells in the guinea pig bladder: structural relationships with smooth muscle and neurons. J Urol. 2005; 173(4): 1385-90[DOI][PubMed]
  • 50. Brading AF, McCloskey KD. Mechanisms of Disease: specialized interstitial cells of the urinary tract--an assessment of current knowledge. Nat Clin Pract Urol. 2005; 2(11): 546-54[DOI][PubMed]
  • 51. Grol S, Essers PB, van Koeveringe GA, Martinez-Martinez P, de Vente J, Gillespie JI. M(3) muscarinic receptor expression on suburothelial interstitial cells. BJU Int. 2009; 104(3): 398-405[DOI][PubMed]
  • 52. de Jongh R, Grol S, van Koeveringe GA, van Kerrebroeck PE, de Vente J, Gillespie JI. The localization of cyclo-oxygenase immuno-reactivity (COX I-IR) to the urothelium and to interstitial cells in the bladder wall. J Cell Mol Med. 2009; 13(9B): 3069-81[DOI][PubMed]
  • 53. Grol S, van Koeveringe GA, de Vente J, van Kerrebroeck PE, Gillespie JI. Regional differences in sensory innervation and suburothelial interstitial cells in the bladder neck and urethra. BJU Int. 2008; 102(7): 870-7[DOI][PubMed]
  • 54. Komuro T. Comparative morphology of interstitial cells of Cajal: ultrastructural characterization. Microsc Res Tech. 1999; 47(4): 267-85[DOI][PubMed]
  • 55. McCloskey KD. Calcium currents in interstitial cells from the guinea-pig bladder. BJU Int. 2006; 97(6): 1338-43[DOI][PubMed]
  • 56. Wu C, Sui GP, Fry CH. Purinergic regulation of guinea pig suburothelial myofibroblasts. J Physiol. 2004; 559: 231-43[DOI][PubMed]
  • 57. Ost D, Roskams T, Van Der Aa F, De Ridder D. Topography of the vanilloid receptor in the human bladder: more than just the nerve fibers. J Urol. 2002; 168(1): 293-7[PubMed]
  • 58. Lagou M, De Vente J, Kirkwood TB, Hedlund P, Andersson KE, Gillespie JI, et al. Location of interstitial cells and neurotransmitters in the mouse bladder. BJU Int. 2006; 97(6): 1332-7[DOI][PubMed]
  • 59. Gillespie JI, Markerink-van Ittersum M, De Vente J. Interstitial cells and cholinergic signalling in the outer muscle layers of the guinea-pig bladder. BJU Int. 2006; 97(2): 379-85[DOI][PubMed]
  • 60. Sanders KM. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology. 1996; 111(2): 492-515[PubMed]
  • 61. Ward SM, Sanders KM, Hirst GD. Role of interstitial cells of Cajal in neural control of gastrointestinal smooth muscles. Neurogastroenterol Motil. 2004; 16 Suppl 1: 112-7[DOI][PubMed]
  • 62. Andersson KE. Changes in bladder tone during filling: pharmacological aspects. Scand J Urol Nephrol Suppl. 1999; 201: 67-72[PubMed]
  • 63. Van Arsdalen KWA. Physiology of micturition and continence 1991;
  • 64. de Groat WC. Anatomy and physiology of the lower urinary tract. Urol Clin North Am. 1993; 20(3): 383-401[PubMed]
  • 65. Drake MJ. The integrative physiology of the bladder. Ann R Coll Surg Engl. 2007; 89(6): 580-5[DOI][PubMed]
  • 66. Beckel JM, Kanai A, Lee SJ, de Groat WC, Birder LA. Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells. Am J Physiol Renal Physiol. 2006; 290(1)-10[DOI][PubMed]
  • 67. D'Andrea MR, Saban MR, Nguyen NB, Andrade-Gordon P, Saban R. Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder. Am J Pathol. 2003; 162(3): 907-23[DOI][PubMed]
  • 68. Du S, Araki I, Mikami Y, Zakoji H, Beppu M, Yoshiyama M, et al. Amiloride-sensitive ion channels in urinary bladder epithelium involved in mechanosensory transduction by modulating stretch-evoked adenosine triphosphate release. Urology. 2007; 69(3): 590-5[DOI][PubMed]
  • 69. Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB, et al. Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377(4-6): 437-48[DOI][PubMed]
  • 70. Streng T, Axelsson HE, Hedlund P, Andersson DA, Jordt SE, Bevan S, et al. Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol. 2008; 53(2): 391-9[DOI][PubMed]
  • 71. Stein RJ, Santos S, Nagatomi J, Hayashi Y, Minnery BS, Xavier M, et al. Cool (TRPM8) and hot (TRPV1) receptors in the bladder and male genital tract. J Urol. 2004; 172(3): 1175-8[DOI][PubMed]
  • 72. Birder L, Kullmann FA, Lee H, Barrick S, de Groat W, Kanai A, et al. Activation of urothelial transient receptor potential vanilloid 4 by 4alpha-phorbol 12,13-didecanoate contributes to altered bladder reflexes in the rat. J Pharmacol Exp Ther. 2007; 323(1): 227-35[DOI][PubMed]
  • 73. Birder LA, Ruggieri M, Takeda M, van Koeveringe G, Veltkamp S, Korstanje C, et al. How does the urothelium affect bladder function in health and disease? ICI-RS 2011. Neurourol Urodyn. 2012; 31(3): 293-9[DOI][PubMed]
  • 74. Bayliss WM, Starling EH. On the relation of enterokinase to trypsin. J Physiol. 1905; 32(2): 129-36[PubMed]
  • 75. Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int. 2004; 93(4): 478-83[PubMed]
  • 76. Gillespie JI. A developing view of the origins of urgency: the importance of animal models. BJU Int. 2005; 96 Suppl 1: 22-8[DOI][PubMed]
  • 77. Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int. 2002; 90(1): 118-29[PubMed]
  • 78. Gillespie JI, Markerink-van Ittersum M, de Vente J. Sensory collaterals, intramural ganglia and motor nerves in the guinea-pig bladder: evidence for intramural neural circuits. Cell Tissue Res. 2006; 325(1): 33-45[DOI][PubMed]
  • 79. Masunaga K, Yoshida M, Inadome A, Iwashita H, Miyamae K, Ueda S. Prostaglandin E2 release from isolated bladder strips in rats with spinal cord injury. Int J Urol. 2006; 13(3): 271-6[DOI][PubMed]
  • 80. Park JM, Yang T, Arend LJ, Schnermann JB, Peters CA, Freeman MR, et al. Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch. Am J Physiol. 1999; 276(1 Pt 2)-36[PubMed]
  • 81. Pinna C, Zanardo R, Puglisi L. Prostaglandin-release impairment in the bladder epithelium of streptozotocin-induced diabetic rats. Eur J Pharmacol. 2000; 388(3): 267-73[PubMed]
  • 82. Andersson KE, Ek A, Persson CG. Effects of prostaglandins on the isolated human bladder and urethra. Acta Physiol Scand. 1977; 100(2): 165-71[DOI][PubMed]
  • 83. Bultitude MI, Hills NH, Shuttleworth KE. Clinical and experimental studies on the action of prostaglandins and their synthesis inhibitors on detrusor muscle in vitro and in vivo. Br J Urol. 1976; 48(7): 631-7[PubMed]
  • 84. Borda E, Contreras-Ortiz N, Gutnisky R, Gimeno MF. In vitro effect of acetylcholine and bethanechol on the contractions of the human detrusor muscle. Influence of prostaglandins. Arch Int Pharmacodyn Ther. 1982; 259(1): 31-9[PubMed]
  • 85. Choo LK, Mitchelson F. The effect of indomethacin and adenosine 5'-triphosphate on the excitatory innervation of the rate urinary bladder. Can J Physiol Pharmacol. 1980; 58(9): 1042-8[PubMed]
  • 86. Burnstock G, Cocks T, Crowe R, Kasakov L. Purinergic innervation of the guinea-pig urinary bladder. Br J Pharmacol. 1978; 63(1): 125-38[PubMed]
  • 87. Downie JW, Larsson C. Prostaglandin involvement in contractions evoked in rabbit detrusor by field stimulation and by adenosine 5'-triphosphate. Can J Physiol Pharmacol. 1981; 59(3): 253-60[PubMed]
  • 88. Johns A, Paton DM. Effect of indomethacin on atropine-resistant transmission in rabbit and monkey urinary bladder: evidence for involvement of prostaglandins in transmission. Prostaglandins. 1977; 13(2): 245-54[PubMed]
  • 89. Jeremy JY, Mikhailidis DP, Dandona P. The rat urinary bladder produces prostacyclin as well as other prostaglandins. Prostaglandins Leukot Med. 1984; 16(2): 235-48[PubMed]
  • 90. Takeda H, Yamazaki Y, Igawa Y, Kaidoh K, Akahane S, Miyata H, et al. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn. 2002; 21(6): 558-65[DOI][PubMed]
  • 91. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006; 175(5): 1773-6[DOI][PubMed]
  • 92. Ikeda M, Kawatani M, Maruyama T, Ishihama H. Prostaglandin facilitates afferent nerve activity via EP1 receptors during urinary bladder inflammation in rats. Biomed Res. 2006; 27(2): 49-54[PubMed]
  • 93. Ishizuka O, Mattiasson A, Andersson KE. Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? J Urol. 1995; 153(6): 2034-8[PubMed]
  • 94. Andersson KE. Current concepts in the treatment of disorders of micturition. Drugs. 1988; 35(4): 477-94[PubMed]
  • 95. Burnstock G. Purinergic cotransmission. Exp Physiol. 2009; 94(1): 20-4[DOI][PubMed]
  • 96. Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol. 2005; 12(10): 875-80[DOI][PubMed]
  • 97. Tanaka I, Nagase K, Tanase K, Aoki Y, Akino H, Yokoyama O. Improvement in neurogenic detrusor overactivity by peripheral C fiber's suppression with cyclooxygenase inhibitors. J Urol. 2010; 183(2): 786-92[DOI][PubMed]
  • 98. Lecci A, Birder LA, Meini S, Catalioto RM, Tramontana M, Giuliani S, et al. Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following experimental cystitis in rats. Br J Pharmacol. 2000; 130(2): 331-8[DOI][PubMed]
  • 99. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009; 19(4): 380-94[DOI][PubMed]
  • 100. Morikawa K, Fukuoka M, Kakiuchi M, Kato H, Ito Y, Gomi Y. Detrusor hyperreflexia induced by intravesical instillation of xylene in conscious rats. Jpn J Pharmacol. 1990; 52(4): 587-95[PubMed]
  • 101. Kibar Y, Irkilata HC, Yaman H, Onguru O, Coguplugil AE, Ergin G, et al. The effect of intravesical acetylsalicylic acid instillation on tissue prostaglandin levels after partial bladder outlet obstruction in rabbits. Neurourol Urodyn. 2011; 30(8): 1646-51[DOI][PubMed]
  • 102. Grol S, Essers PB, van Koeveringe GA, de Vente J, Gillespie JI. Ubiquitin hydrolase (protein gene product 9.5) in the obstructed bladder: evidence for tissue remodelling involving a subset of interstitial cells. BJU Int. 2009; 104(5): 698-706[DOI][PubMed]
  • 103. de Jongh R, van Koeveringe GA, van Kerrebroeck PE, Markerink-van Ittersum M, de Vente J, Gillespie JI. Alterations to network of NO/cGMP-responsive interstitial cells induced by outlet obstruction in guinea-pig bladder. Cell Tissue Res. 2007; 330(1): 147-60[DOI][PubMed]
  • 104. Gillespie JI, Markerink-van Ittersum M, De Vente J. Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: evidence for distinct populations of sub-urothelial interstitial cells. Cell Tissue Res. 2006; 325(2): 325-32[DOI][PubMed]
  • 105. Sawyer RT, Parsons CE, Fontenot AP, Maier LA, Gillespie MM, Gottschall EB, et al. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol. 2004; 31(1): 122-30[DOI][PubMed]
  • 106. de Jongh R, van Koeveringe GA, van Kerrebroeck PE, Markerink-van Ittersum M, de Vente J, Gillespie JI. The effects of exogenous prostaglandins and the identification of constitutive cyclooxygenase I and II immunoreactivity in the normal guinea pig bladder. BJU Int. 2007; 100(2): 419-29[DOI][PubMed]
  • 107. Lagou M, Gillespie J, Kirkwood T, Harvey I, Drake MJ. Muscarinic stimulation of the mouse isolated whole bladder: physiological responses in young and ageing mice. Auton Autacoid Pharmacol. 2006; 26(3): 253-60[DOI][PubMed]
  • 108. de Jongh R, van Koeveringe GA, van Kerrebroeck PE, Markerink-van Ittersum M, de Vente J, Gillespie JI. Damage to the bladder neck alters autonomous activity and its sensitivity to cholinergic agonists. BJU Int. 2007; 100(4): 919-29[DOI][PubMed]
  • 109. Klarskov N, Lose G. Urethral pressure reflectometry and pressure profilometry in healthy volunteers and stress urinary incontinent women. Neurourol Urodyn. 2008; 27(8): 807-12[DOI][PubMed]
  • 110. Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol. 1999; 57(9): 965-73[PubMed]
  • 111. Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci U S A. 1998; 95(15): 8991-6[PubMed]
  • 112. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem. 1998; 273(25): 15553-8[PubMed]
  • 113. Truss MC, Stief CG, Uckert S, Becker AJ, Schultheiss D, Machtens S, et al. Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol. 2000; 18(6): 439-43[PubMed]
  • 114. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002; 90(9): 836-9[PubMed]
  • 115. McVary KT, Kaufman J, Young JM, Tseng LJ. Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension. Int J Clin Pract. 2007; 61(11): 1843-9[DOI][PubMed]
  • 116. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007; 177(4): 1401-7[DOI][PubMed]
  • 117. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008; 53(6): 1236-44[DOI][PubMed]
  • 118. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology. 2007; 148(3): 1019-29[DOI][PubMed]
  • 119. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 2006; 98(6): 1259-63[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments